Mei-Yin Polley to Prospective Studies
This is a "connection" page, showing publications Mei-Yin Polley has written about Prospective Studies.
Connection Strength
0.242
-
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 06 18; 135(25):2224-2234.
Score: 0.102
-
Power estimation in biomarker studies where events are already observed. Clin Trials. 2017 Dec; 14(6):621-628.
Score: 0.083
-
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Dec; 29(12):3067-3076.
Score: 0.032
-
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
Score: 0.014
-
Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009 Feb; 11(1):59-68.
Score: 0.011